论文部分内容阅读
Risedronate(以下简称Ris)是一种吡啶二磷酸盐抑制骨吸收剂,可治疗骨质疏松症。为测定口服Ris疗法对绝经早期妇女骨质丢失的疗效,停药对骨质的影响及Ris的安全性和耐受性,对志愿参加研究的111例绝经在1/2～5年,腰椎骨质正常的妇女进行双盲、安慰剂对照研究。患者均为高加索人。随机分为安慰剂组(Pg)36例(每日口服安慰剂胶囊2个);每日组(Dg)37例(口服Ris胶囊5mg/d);周期组(Cg)38例(每月头2周口服Ris5mg/d,剩余时间服安慰剂)。疗程2年,停药1年后随访。疗效测定:定期检测①腰椎骨矿物质密度(BMD);②股骨颈、转子区和Wards三角区BMD;③骨转换改变查尿d-pyr/肌酐(Cr)(骨吸收标记)和碱性磷酸酶
Risedronate (hereinafter referred to as Ris) is a pyridinedic diphosphate inhibitory bone resorption for the treatment of osteoporosis. To determine the effect of oral Ris therapy on bone loss in early postmenopausal women, the effect of discontinuation on bone quality and the safety and tolerability of Ris, 111 menopause women who participated in the study were selected as menopausal for 1-2 years, Normal-quality women underwent a double-blind, placebo-controlled study. The patients were Caucasian. (Pg) were randomly divided into placebo group (Pg) 36 cases (daily oral placebo capsule 2); daily group (Dg) 37 cases (oral Ris capsule 5mg / d); cycle group (Cg) 38 cases 2 weeks of oral Ris5mg / d, the remaining time placebo). Treatment for 2 years, 1 year after drug withdrawal. The curative effect was measured: BMD of lumbar vertebra was measured regularly; BMD of femoral neck, trochanter area and Wards triangle area were measured; ③D-pyr / Cr (bone resorption marker) and alkaline phosphatase Enzymes